Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard

Nicolas Mottet, Maria De Santis, Erik Briers, Liam Bourke, Silke Gillessen, Jeremy P Grummet, Thomas B Lam, Henk G van der Poel, Olivier Rouvière, Roderick C N van den Bergh, Philip Cornford

Research output: Contribution to journalComment/debatepeer-review

Abstract

Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.

Original languageEnglish
JournalEuropean Urology
Early online date2 Nov 2017
DOIs
Publication statusE-pub ahead of print - 2 Nov 2017

Fingerprint

Dive into the research topics of 'Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard'. Together they form a unique fingerprint.

Cite this